Olecranon bursitis

disease
On this page

Also known as bursitis of olecranonelbow bursitis (& olecranon)

Summary

Olecranon bursitis (MONDO:0001557) is a disease and 1 clinical trial. A subtype of enthesopathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameolecranon bursitis
Mondo IDMONDO:0001557
DOIDDOID:12581
ICD-10-CMM70.2
SNOMED CT425940002
UMLSC0263962
MedGen538225
Anatomy (UBERON)UBERON:0001490
Is cancer (heuristic)no

Also known as: bursitis of olecranon · elbow bursitis (& olecranon) · olecranon bursitis

Disease family

This is a subtype of enthesopathy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorderenthesopathyolecranon bursitis

Related subtypes (4): pes anserinus tendinitis or bursitis, tibial collateral ligament bursitis, fibular collateral ligament bursitis, enthesitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01406652Not specifiedCOMPLETEDOptimisation of the Treatment of Infectious Bursitis

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.